Jul 10, 2026Multi-sector
Growth equity fund closes $1.2B Fund IV
Upper-middle-market software and healthcare services focus; first close oversubscribed.
Insights
Capital intelligence for decision-makers.
Market dashboard, investor guides, perspectives, and research - structured for founders, boards, and institutional investors.
Market dashboard, investor guides, and research drawn from live mandate activity across equity, debt, and M&A. Written for founders, boards, and institutional investors who need usable framing, not headline recycling. For institutional and professional use only.
Featured Research · White Paper
The Q4 Imperative: Why the Fourth Quarter Shapes Investment and M&A Outcomes
How year-end deadlines, record dry powder and the exit backlog make Q4 2026 the quarter that decides deal outcomes, and what sellers, sponsors and buyers should do before December 31.
September 2026 · 12-page PDF
- $229.2B
- US PE exit value in Q4 2025
- $1.1T+
- US PE dry powder entering Q4 2026
- Nov 15
- Last practical date to sign for a 2026 close
Featured Booklet · Free Download
The 14-Week Growth-Round Equity Process Map
How growth-stage equity cycles lengthened, and what founders should do each phase from readiness through close.
- Fourteen weeks is now the operational base case for institutional growth rounds, not eight.
- The four weeks before launch are the highest-leverage period: data room, prospect map, narrative.
- Compare term sheets on structure and exit-scenario dilution, not headline valuation alone.
Six to twelve months from a growth process? Take the raise readiness diagnostic before you read the full phase map.
Keningford Partners Research
The 14-Week Growth-Round Equity Process Map
18 min read · PDF Booklet
FAQ
Frequently asked questions
Cooley GO’s Quarterly Venture Financing Reports place the median time-to-close for US growth-stage equity rounds at roughly fourteen weeks in H1 2025, against an eight-week median in 2023. Keningford Partners expects the fourteen-to-eighteen-week range to remain the operational base case through 2026 and 2027, because the structural drivers, deeper diligence, larger syndicates, harder term-sheet structure, are not cyclical.
Capital Markets Dashboard
This week
Week of July 7, 2026
Jul 8, 2026Life Sciences
Life sciences venture fund launches $350M vehicle
Growth-stage therapeutics and sustainable materials mandate with family office anchor commitments.
Illustrative weekly snapshot for market context, not live market data or investment advice.
Investor Guides
How institutional capital works
Featured
18 min read
The 14-Week Growth-Round Equity Process Map
How growth-stage equity cycles lengthened, and what founders should do each phase from readiness through close.
10 min read
How Family Offices Evaluate Opportunities
What family offices weigh beyond headline returns: alignment, governance, liquidity, and relationship quality.
12 min read
How LPs Select Funds
How institutional limited partners underwrite emerging and established managers in a selective deployment environment.
11 min read
Debt vs Equity
A practical framework for founders evaluating financing alternatives without defaulting to equity dilution.
13 min read
How Due Diligence Works
What institutional investors examine in financial, commercial, and legal diligence, and how to prepare.
11 min read
What Makes a Great Investment Memo
The elements institutional investors expect in a concise, credible investment memorandum.
Market Insights
Perspectives from our team
Market Insights
Vertical AI Capital Trajectory: What H2 2026 Looks Like for Growth Rounds
Vertical AI has become one of the most contested growth-stage capital destinations. Investors are paying for workflow depth, retention, and defensible data - not model wrappers.
- What Investors Are Underwriting
- Valuation and Structure
- Implications for Founders
Read more
Market Insights
Healthcare AI Equity: What Growth-Stage Round Data Actually Shows
Healthcare AI rounds in 2025–2026 closed at premium multiples relative to horizontal software - but only for assets with reimbursement clarity, clinical validation, and enterprise distribution.
Read more
Market Insights
Family Office Allocation Shift: H2 2026 Watch
Family offices are redeploying toward direct investments, co-investments, and structured equity - with longer hold periods and sharper governance expectations than the prior cycle.
Read more
Market Insights
The Debt-First Capital Stack: A Founder's Toolkit
When equity is expensive, growth-stage founders are rebuilding the capital stack with venture debt, structured credit, and hybrid instruments, without defaulting to dilution.
Read more
Market Insights
Founder Liquidity Without IPO: Secondary Tender Structures
As the median time from Series A to IPO stretches past a decade, secondary tenders and structured liquidity programs have become a core tool for retention - not a sign of weakness.
Read more
Market Insights
The Down-Round Playbook: Structural Options for Founders in 2026
Down rounds are no longer exceptional. Founders facing a reset should compare four structural paths - and three questions - before signing terms.
Read more
Research
Reports & primers
White PaperCross-Sector12 pages
The Q4 Imperative: Why the Fourth Quarter Shapes Investment and M&A Outcomes
How year-end deadlines, record dry powder and the exit backlog make Q4 2026 the quarter that decides deal outcomes, and what sellers, sponsors and buyers should do before December 31.
Market OutlookEnergy & Infrastructure24 pages
Q2 2026 Energy & Infrastructure M&A Outlook
Deal velocity, valuation benchmarks, and capital availability across power, renewables, and midstream assets in North America and the Middle East.
Capital Markets ReviewCross-Sector18 pages
H1 2026 Middle Market Capital Markets Review
A structured review of raise activity, pricing dynamics, and investor positioning across growth equity, private credit, and structured capital.
Sector PrimerTechnology & Life Sciences20 pages
2026 Biotech & Life Sciences Financing Landscape
How growth-stage biotech and deep-tech companies are positioning for institutional capital across venture crossover, strategic capital, and project finance.
Sector PrimerTechnology & Life Sciences16 pages
Healthcare AI Equity Trajectory: 2026 Sector Review
How growth-stage healthcare AI companies are positioning for institutional capital - reimbursement clarity, clinical validation, and enterprise distribution as the new underwriting baseline.
Sector PrimerCross-Sector14 pages
Founder Liquidity Without IPO: Secondary & Tender Structures
A practical primer on secondary tenders, company-sponsored repurchases, and structured liquidity - when they work, how they are priced, and what boards should prepare.